Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure

Article

关键词: RECOMBINANT GROWTH-HORMONE;    DILATED CARDIOMYOPATHY;    MYOCARDIAL-INFARCTION;    BODY-COMPOSITION;    DOUBLE-BLIND;    FACTOR-I;    DEFICIENCY;    ACTIVATION;    MYOCYTES;    PEPTIDE;   

DOI  :  10.1161/hc3601.095575

来源: SCIE

【 摘 要 】

Background-Ghrelin is a novel growth hormone (GH)-releasing peptide that may also induce vasodilation and stimulate feeding through GH-independent mechanisms. We investigated whether ghrelin improves left ventricular (LV) dysfunction and attenuates cardiac cachexia in rats with chronic heart failure (CHF). Methods and Results-Ligation of the left coronary artery or sham operation was performed; 4 weeks after surgery, rat ghrelin (100 mug/kg SC BID) or saline was administered for 3 weeks. Echocardiography and cardiac catheterization were performed. Serum GH and insulin-like growth factor-1 were significantly higher in both CHF and sham rats treated with ghrelin than in those given placebo (P <0.05 for both). CHF rats given placebo showed an impaired increase in body weight compared with sham rats given placebo (P <0.05). CHF rats treated with ghrelin, however, showed a significantly greater increase in body weight than those given placebo (+ 10% versus +3%, P <0.05). They showed significantly higher cardiac output (315 +/- 49 versus 266 +/- 31 mL (.) min(-1) (.) kg(-1), P <0.05) and LV dP/dt(max) (5738 +/- 908 versus 4363 +/- 973 mm Hg/s, P <0.05) than CHF rats given placebo. Ghrelin increased diastolic thickness of the noninfarcted posterior wall, inhibited LV enlargement, and increased LV fractional shortening in CHF rats (from 15 +/-3% to 19 +/-3%, P <0.05). Conclusions-Chronic subcutaneous administration of ghrelin improved LV dysfunction and attenuated the development of LV remodeling and cardiac cachexia in rats with CHF.

【 授权许可】

Free